Literature DB >> 28095156

Lung Cancer Risk Prediction Model Incorporating Lung Function: Development and Validation in the UK Biobank Prospective Cohort Study.

David C Muller1, Mattias Johansson1, Paul Brennan1.   

Abstract

Purpose Several lung cancer risk prediction models have been developed, but none to date have assessed the predictive ability of lung function in a population-based cohort. We sought to develop and internally validate a model incorporating lung function using data from the UK Biobank prospective cohort study. Methods This analysis included 502,321 participants without a previous diagnosis of lung cancer, predominantly between 40 and 70 years of age. We used flexible parametric survival models to estimate the 2-year probability of lung cancer, accounting for the competing risk of death. Models included predictors previously shown to be associated with lung cancer risk, including sex, variables related to smoking history and nicotine addiction, medical history, family history of lung cancer, and lung function (forced expiratory volume in 1 second [FEV1]). Results During accumulated follow-up of 1,469,518 person-years, there were 738 lung cancer diagnoses. A model incorporating all predictors had excellent discrimination (concordance (c)-statistic [95% CI] = 0.85 [0.82 to 0.87]). Internal validation suggested that the model will discriminate well when applied to new data (optimism-corrected c-statistic = 0.84). The full model, including FEV1, also had modestly superior discriminatory power than one that was designed solely on the basis of questionnaire variables (c-statistic = 0.84 [0.82 to 0.86]; optimism-corrected c-statistic = 0.83; pFEV1 = 3.4 × 10-13). The full model had better discrimination than standard lung cancer screening eligibility criteria (c-statistic = 0.66 [0.64 to 0.69]). Conclusion A risk prediction model that includes lung function has strong predictive ability, which could improve eligibility criteria for lung cancer screening programs.

Entities:  

Mesh:

Year:  2017        PMID: 28095156     DOI: 10.1200/JCO.2016.69.2467

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  38 in total

1.  A novel biomarker protein panel for lung cancer, a promising first step.

Authors:  Camilo Molina-Romero; Edgar Vergara; Oscar Arrieta
Journal:  Transl Lung Cancer Res       Date:  2018-12

2.  Selecting high-risk individuals for lung cancer screening; the use of risk prediction models vs. simplified eligibility criteria.

Authors:  Rudolf Kaaks; Anika Hüsing; Renée T Fortner
Journal:  Ann Transl Med       Date:  2017-10

3.  Risk models to select high risk candidates for lung cancer screening.

Authors:  Matthew B Schabath
Journal:  Ann Transl Med       Date:  2018-02

4.  Opportunities, challenges and expectations management for translating biobank research to precision medicine.

Authors:  Christopher J O'Donnell
Journal:  Eur J Epidemiol       Date:  2020-02-28       Impact factor: 8.082

Review 5.  Selecting lung cancer screenees using risk prediction models-where do we go from here.

Authors:  Martin C Tammemägi
Journal:  Transl Lung Cancer Res       Date:  2018-06

Review 6.  Blood based biomarkers beyond genomics for lung cancer screening.

Authors:  Samir M Hanash; Edwin Justin Ostrin; Johannes F Fahrmann
Journal:  Transl Lung Cancer Res       Date:  2018-06

7.  Assessment of Lung Cancer Risk on the Basis of a Biomarker Panel of Circulating Proteins.

Authors:  Florence Guida; Nan Sun; Leonidas E Bantis; David C Muller; Peng Li; Ayumu Taguchi; Dilsher Dhillon; Deepali L Kundnani; Nikul J Patel; Qingxiang Yan; Graham Byrnes; Karel G M Moons; Anne Tjønneland; Salvatore Panico; Claudia Agnoli; Paolo Vineis; Domenico Palli; Bas Bueno-de-Mesquita; Petra H Peeters; Antonio Agudo; Jose M Huerta; Miren Dorronsoro; Miguel Rodriguez Barranco; Eva Ardanaz; Ruth C Travis; Karl Smith Byrne; Heiner Boeing; Annika Steffen; Rudolf Kaaks; Anika Hüsing; Antonia Trichopoulou; Pagona Lagiou; Carlo La Vecchia; Gianluca Severi; Marie-Christine Boutron-Ruault; Torkjel M Sandanger; Elisabete Weiderpass; Therese H Nøst; Kostas Tsilidis; Elio Riboli; Kjell Grankvist; Mikael Johansson; Gary E Goodman; Ziding Feng; Paul Brennan; Mattias Johansson; Samir M Hanash
Journal:  JAMA Oncol       Date:  2018-10-11       Impact factor: 31.777

8.  Applying Risk Prediction Models to Optimize Lung Cancer Screening: Current Knowledge, Challenges, and Future Directions.

Authors:  Lori C Sakoda; Louise M Henderson; Tanner J Caverly; Karen J Wernli; Hormuzd A Katki
Journal:  Curr Epidemiol Rep       Date:  2017-10-24

9.  [China National Lung Cancer Screening Guideline with Low-dose Computed 
Tomography (2018 version)].

Authors:  Qinghua Zhou; Yaguang Fan; Ying Wang; Youlin Qiao; Guiqi Wang; Yunchao Huang; Xinyun Wang; Ning Wu; Guozheng Zhang; Xiangpeng Zheng; Hong Bu; Yin Li; Sen Wei; Liang'an Chen; Chengping Hu; Yuankai Shi; Yan Sun
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2018-02-20

10.  Chronic disease research in Europe and the need for integrated population cohorts.

Authors:  Paul Brennan; Markus Perola; Gert-Jan van Ommen; Elio Riboli
Journal:  Eur J Epidemiol       Date:  2017-10-06       Impact factor: 8.082

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.